MGC Pharmaceuticals Ltd
TM Rescue · Minimum three (3) year exclusive worldwide
1 supply and distribution agreement signed with leading European nutraceuticals producer and distributor, Swiss PharmaCan AG, for the distribution of ArtemiC™ Rescue as a food supplement · This agreement follows the completion of a successful phase II double-blind, placebo-controlled clinical trial on 50 COVID-19 patients across Israel and India that met all its primary and secondary endpoints · Agreement includes minimum wholesale order quantity to MGC Pharma of 40,000 units of ArtemiC™ Rescue per quarter · Initial wholesale order of 10,000 units received by MGC Pharma, which has a total retail market value of US$850,000 for Swiss PharmaCan AG
MGC Pharmaceuticals Ltd signs supply and distribution agreement with Swiss PharmaCan AG for ArtemiC™ Rescue
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
MGC Pharmaceuticals Ltd signs supply and distribution agreement with Swiss PharmaCan AG for ArtemiC™ Rescue
proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.
Relay Medical Reports Glow LifeTech Secures Exclusive North American Rights to ArtemiC(TM) Following Successful COVID-19 Phase II Clinical Trial
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Relay Medical Corp.: Relay Medical Reports Glow LifeTech Secures Exclusive North American Rights to ArtemiC Following Successful COVID-19 Phase II Clinical Trial
Relay or the
Company ), a technology developer and innovator, and Glow LifeTech Ltd. (
Glow ), a private company in which Relay holds a significant equity interest, are pleased to report that Glow has executed an agreement with Swiss Pharmacan AG ( the agreement ) for exclusive North American and Carribean sales and distribution rights for ArtemiC , a natural health product based on Glow s MyCell Technology ( MyCell ) which recently reported successful results from a COVID-19 Phase II clinical trial (see Relay s release dated Jan 14, 2021).